As Aurinia Pharmaceuticals explores a potential sale and refreshes its board following pushback from MKT Capital and another investor group, the drugmaker has agreed to name its founder Robert Foster to a director seat.
Aurinia said Thursday it will cooperate with MKT Capital under an agreement that they’ve hashed out. In a statement, chair Daniel Billen called the process a “constructive collaboration,” and MKT founder Antoine Khalife said the firm is “encouraged” by the “productive discussions” with the board.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.